CORA Cork Open Research Archive
Cartlann Taighde Oscailte Chorcaí

Title	Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial
Authors	Sharp, Andrew;Cornforth, Christine;Jackson, Richard;Harrold, Jane;Turner, Mark A.;Kenny, Louise C.;Baker, Philip N.;Johnstone, Edward D.;Khalil, Asma;von Dadelszen, Peter;Papageorghiou, Aris T.;Alfirevic, Zarko
Publication date	2018
Original Citation	Sharp, A., Cornforth, C., Jackson, R., Harrold, J., Turner, M. A., Kenny, L. C., Baker, P. N., Johnstone, E. D., Khalil, A., von Dadelszen, P., Papageorghiou, A. T. and Alfirevic, Z. (2018) 'Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial', The Lancet Child and Adolescent Health, 2(2), pp. 93-102. doi: 10.1016/S2352-4642(17)30173-6
Type of publication	Article (peer-reviewed)
Link to publisher's version	https://www.sciencedirect.com/science/article/pii/S2352464217301736 - 10.1016/S2352-4642(17)30173-6
Rights	© 2018, the Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 licence. - https://creativecommons.org/licenses/by-nc-nd/4.0/
Download date	2026-11-05 23:34:34
Item downloaded from	https://hdl.handle.net/10468/5604

UCC
University College Cork, Ireland
Coláiste na hOllscoile Corcaigh

THE LANCET
Child & Adolescent Health

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Sharp A, Cornforth C, Jackson R, et al, on behalf of the STRIDER group. Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial. *Lancet Child Adolesc Health* 2017; published online Dec 6. http://dx.doi.org/10.1016/S2352-4642(17)30173-6.

Supplementary Table 1: Longitudinal analysis of angiogenic biomarkers

sEng (ng/ml)

Time	**Placebo**	**Sildenafil**	**Total**
Pretreatment	32·12 (20·805, 58·24)	37·805 (19·523, 49·208)	33·61 (20·205, 57·72)
2 hours post	30·75 (18·62, 54·273)	34·285 (17·372, 49·737)	31·55 (17·892, 52·55)
3 - 4 days	28·675 (18·005, 51·572)	33·625 (17·235, 50·463)	30·08 (17·235, 50·89)
7 - 8 days	30·42 (21·28, 53·703)	34·775 (18·215, 53·675)	32·99 (18·385, 54·025)
10 - 11 days	25·885 (19·312, 49·67)	32·775 (17·312, 48·76)	30·13 (18·247, 49·62)
13 - 14 days	32·23 (23·275, 50·905)	26·77 (18·5, 48·88)	30·115 (20·455, 49·805)
ANOVA	Treatment	Time	Treatment*Time Interaction
	0·43	0·89	0·99

sFlt-1 (pg/ml)

Pretreatment	6975 (5235·5, 10149·25)	6894 (5025, 11146)	6894 (5025, 10380)
2 hours post	6792 (4678·5, 9712·5)	6370 (4594, 9874)	6625·5 (4627·75, 9808·75)
3 - 4 days	7522 (5592·5, 9048·5)	7402 (4941·5, 10510·75)	7522 (5135, 9253)
7 - 8 days	7834 (5574·75, 9652·75)	7335 (4518·5, 9816)	7652 (5213, 9812)
10 - 11 days	7852 (5685·5, 10025·25)	6980 (4752, 8416·5)	7498·5 (5020, 9699·75)
13 - 14 days	7325 (6025, 9993·5)	6707 (5606, 9827·5)	7304·5 (5766·25, 9993·75)
ANOVA	Treatment	Time	Treatment*Time Interaction
	0·64	0·98	0·95

PGF (pg/ml)

Pretreatment	25 (13, 42)	21 (14, 42)	22 (13, 42)
2 hours post	23 (11·5, 41·5)	26 (15, 49)	23·5 (12, 43·75)
3 - 4 days	23 (13, 48·5)	22 (16, 37)	23 (13, 43)
7 - 8 days	35·5 (15·5, 68·75)	18 (12, 35)	24 (13, 49)
10 - 11 days	34 (14·25, 72·25)	28 (17·25, 46·75)	31·5 (16, 49·75)
13 - 14 days	36 (16, 64)	20 (13, 40)	26 (15, 50·5)
ANOVA	Treatment	Time	Treatment*Time Interaction
	0·07	0·89	0·81

Supplementary Table 1: Longitudinal analysis of angiogenic biomarkers

sFlt-1:PGF ratio

Pretreatment	316·45 (161·4, 592·975)	365 (182·2, 583·1)	343·9 (167·2, 591·6)
2 hours post	295·3 (150·65, 599·15)	355·3 (137·4, 533·1)	325·1 (148·85, 568·1)
3 - 4 days	336·5 (133·2, 634·25)	399·55 (150·5, 533·925)	367·3 (142·3, 562·3)
7 - 8 days	258·15 (131·7, 497·5)	401·8 (189·3, 632·8)	319 (169·9, 545·6)
10 - 11 days	233·9 (109·325, 628·2)	273·45 (131·4, 464·75)	248·35 (111·175, 490·05)
13 - 14 days	208·1 (125·4, 538·25)	421·4 (216·85, 470·3)	313·6 (170·875, 473·425)
ANOVA	Treatment	Time	Treatment*Time Interaction
	0·047	0·66	0·87

* Median (interquartile range)